FAK: A Potential Target for Cancer Therapy

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase with critical roles in cancer progression, metastasis, and recurrence.
• FAK possesses both enzymatic and scaffolding functions, interacting with over 50 proteins.
• Existing FAK inhibitors primarily target kinase activity, neglecting its scaffolding functions.

Purpose of the Study:

• To explore PROTAC technology as a novel strategy for FAK degradation.
• To evaluate the potential of PROTACs in eliminating both enzymatic and scaffolding functions of FAK.
• To investigate combination therapies involving FAK degradation for enhanced anticancer efficacy.

Main Methods:

• Development of FAK-targeting Proteolysis Targeting Chimeras (PROTACs).
• Assessment of PROTAC efficacy in degrading the complete FAK protein.
• Exploration of dual-target degradation and inhibitor-degrader strategies.

Main Results:

• Several FAK-targeting PROTACs have been successfully developed.
• PROTACs demonstrate the potential to degrade the entire FAK protein, addressing both its functions.
• Promising results indicate enhanced anticancer efficacy through FAK degradation strategies.

Conclusions:

• PROTAC technology presents a novel approach to target FAK by inducing its complete degradation.
• Degrading FAK, rather than just inhibiting its kinase activity, may overcome limitations of current therapies.
• Combination therapies involving FAK degradation hold significant promise for improving outcomes in cancer treatment.